The Real Impact Of ‘Cures’: The Hype Means Something
It is hard to find anything in the 21st Century Cures Act that justifies the hyperbole around its signing – or the criticism that it undermines patient safety. But, for the biopharma industry, the hype is important as a sign that pro-innovation messages have bipartisan appeal.
You may also be interested in...
The Upton-DeGette legislation wasn’t going to be part of the omnibus bill moving through Congress this week, but its original concepts – creating more clarity on CMS reimbursement – seem as critical as ever.
Primary sponsors of the 21st Century Cures Act are trying to get the band back together. Is there hope to recapture a bipartisan, pro-innovation spirit in the current US Congress?
In the wake of 21st Century Cures legislation, next commissioner will have strong support across party lines to undertake smarter regulation aimed at improving the efficiency of the drug development process, former FDA head McClellan says.